Vitro Biopharma, Inc. Quarterly Research and Development Expense in USD from Q2 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
Summary
Vitro Biopharma, Inc. quarterly/annual Research and Development Expense history and growth rate from Q2 2010 to Q2 2024.
  • Vitro Biopharma, Inc. Research and Development Expense for the quarter ending July 31, 2024 was $126K, a 279% increase year-over-year.
  • Vitro Biopharma, Inc. Research and Development Expense for the twelve months ending July 31, 2024 was $522K, a 354% increase year-over-year.
  • Vitro Biopharma, Inc. annual Research and Development Expense for 2023 was $206K, a 32.6% increase from 2022.
  • Vitro Biopharma, Inc. annual Research and Development Expense for 2022 was $156K.
  • Vitro Biopharma, Inc. annual Research and Development Expense for 2015 was $152K, a 16.8% decline from 2014.
Research and Development Expense, Trailing 12 Months (USD)
Research and Development Expense, Quarterly (USD)
Research and Development Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $522K $126K +$92.5K +279% May 1, 2024 Jul 31, 2024 10-Q 2024-09-16
Q1 2024 $429K $140K +$73.2K +110% Feb 1, 2024 Apr 30, 2024 10-Q 2024-05-31
Q4 2023 $356K $156K +$149K +2186% Nov 1, 2023 Jan 31, 2024 10-Q 2024-03-14
Q3 2023 $206K $100K +$91.5K +1074% Aug 1, 2023 Oct 31, 2023 10-K 2024-01-29
Q2 2023 $115K $33.1K -$45.9K -58.1% May 1, 2023 Jul 31, 2023 10-Q 2024-09-16
Q1 2023 $161K $66.4K +$976 +1.49% Feb 1, 2023 Apr 30, 2023 10-Q 2024-05-31
Q4 2022 $160K $6.83K +$4.26K +166% Nov 1, 2022 Jan 31, 2023 10-Q 2024-03-14
Q3 2022 $156K $8.52K Aug 1, 2022 Oct 31, 2022 10-K 2024-01-29
Q2 2022 $79.1K May 1, 2022 Jul 31, 2022 10-Q 2023-08-28
Q1 2022 $65.5K Feb 1, 2022 Apr 30, 2022 10-Q 2023-06-13
Q4 2021 $2.57K Nov 1, 2021 Jan 31, 2022 10-Q 2023-03-14
Q1 2015 $183K $56.9K +$6.23K +12.3% Feb 1, 2015 Apr 30, 2015 10-Q 2016-01-22
Q4 2014 $177K $29.9K -$6K -16.7% Nov 1, 2014 Jan 31, 2015 10-Q 2015-03-24
Q3 2014 $183K $52K Aug 1, 2014 Oct 31, 2014 10-K 2016-09-22
Q2 2014 $44.1K +$16.5K +60.1% May 1, 2014 Jul 31, 2014 10-Q 2014-09-22
Q1 2014 $50.7K +$8.1K +19% Feb 1, 2014 Apr 30, 2014 10-Q 2016-01-22
Q4 2013 $35.9K Nov 1, 2013 Jan 31, 2014 10-Q 2015-03-24
Q2 2013 $27.5K -$1.43K -4.93% May 1, 2013 Jul 31, 2013 10-Q 2014-09-22
Q1 2013 $42.6K -$133 -0.31% Feb 1, 2013 Apr 30, 2013 10-Q 2014-06-19
Q3 2012 $126K $24.9K -$7.48K -23.1% Aug 1, 2012 Oct 31, 2012 10-K 2014-02-12
Q2 2012 $134K $29K -$6.91K -19.3% May 1, 2012 Jul 31, 2012 10-Q/A 2012-10-17
Q1 2012 $141K $42.7K +$15.1K +54.9% Feb 1, 2012 Apr 30, 2012 10-Q/A 2012-06-22
Q4 2011 $125K $29.6K -$12.6K -29.9% Nov 1, 2011 Jan 31, 2012 10-Q 2012-03-21
Q3 2011 $138K $32.4K Aug 1, 2011 Oct 31, 2011 10-K/A 2012-02-16
Q2 2011 $35.9K -$3.78K -9.52% May 1, 2011 Jul 31, 2011 10-Q/A 2012-10-17
Q1 2011 $27.6K Feb 1, 2011 Apr 30, 2011 10-Q/A 2012-06-22
Q4 2010 $42.2K Nov 1, 2010 Jan 31, 2011 10-Q 2012-03-21
Q2 2010 $39.7K May 1, 2010 Jul 31, 2010 10-Q/A 2011-10-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.